Regulation - Janssen, Markets & Marketing

Filter

Popular Filters

FDA delays once-a-day Prezista approval; finds counterfeit of Teva's Adderall

30-05-2012

US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Therapeutics division has received a complete…

AdderallAnti-viralsGenericsJanssenJohnson & JohnsonMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalPrezistaRegulationTeva Pharmaceutical Industries

Back to top